Shon Remich | MD, and CMO,
ARMR Sciences

Dr. Shon Remich is a passionate physician-scientist who has dedicated more than 25 years of his career to public and global health. He has been at the forefront of some of the largest public health challenges of the last century. During his 23-year military career, he completed board certification in Pediatics and postdoctoral programs in Clinical Pharmacology (Georgetown/Walter Reed) and Allergy/Immunology (Walter Reed/NIH). As a military officer he completed two overseas postings in Kenya, totaling eight years, where he directed the clinical development of drugs (GMP IV artesunate) and vaccines (RTS,S) as contermeasures for malaria. During his second Kenya posting, he led the President's Emergency Plan for AIDS Relief (PEPFAR) for the Department of Defense. Following his return from Kenya he retuned to the Walter Reed Army Institute of Research (D.C.) where he directed the Translational Medicine department and Bioproduction facility as well as chaired the the military's largest Institutional Review Board. As the director of Translational Medicine, his team conducted multipe clinical trails for complex and debilitating diseases (HIV, Anthrax, Malaria, Hantavirus, Plague, Shigella, E.coli, and Influenza), including the first Ebola vaccine (VZV-Ebola) trial in the United States. After his military career, he joined Pfizer's clinical development team, supporting the U.S. licensure of the Japanese Encephalitis vaccine (Ticovax) and later played a key role in the development of the nation's first COVID vaccine (Comirnaty). He then joined the vaccine business unit at Takeda to support the EMA approval of Qdenga, a dengue vaccine. After a short time at BioNTech, where he led the latent viral program, Dr. Remich joined a newly formed biotech company, ARMR Sciences. ARMR Sciences is committed to developing solutions to address the current epidemic and public health emergency related to opioid poisoning and overdose.